Oncopeptides has been granted a patent for a novel lyophilized pharmaceutical preparation containing melphalan flufenamide and excipients like hydroxypropyl-ß-cyclodextrin. The formulation is directly soluble in water and is intended for cancer therapy. GlobalData’s report on Oncopeptides gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Oncopeptides AB - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Oncopeptides, Peptide pharmacophores was a key innovation area identified from patents. Oncopeptides's grant share as of April 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.

Lyophilized pharmaceutical preparation for cancer therapy

Source: United States Patent and Trademark Office (USPTO). Credit: Oncopeptides AB

A recently granted patent (Publication Number: US11896668B2) discloses a lyophilized pharmaceutical preparation that is directly soluble in a physiologically acceptable aqueous solution. The formulation includes melphalan flufenamide or its salt, along with hydroxypropyl-ß-cyclodextrin and/or sulfobutylether-ß-cyclodextrin. The amount of cyclodextrin is specified to be between 10-100% by weight of melphalan flufenamide, with the formulation containing less than 0.5% by weight of organic solvents. Additionally, certain claims specify the use of either hydroxypropyl-ß-cyclodextrin or sulfobutylether-ß-cyclodextrin as the sole excipient, with trace amounts of an organic solvent permitted in some instances.

Furthermore, the patent claims cover various pharmaceutical compositions consisting of the lyophilized preparation and a physiologically acceptable solution, with glucose solution being specifically mentioned. The formulations are designed to ensure solubility in aqueous solutions, with specific ratios of melphalan flufenamide and cyclodextrins outlined in the claims. The patent also emphasizes the use of either hydroxypropyl-ß-cyclodextrin or sulfobutylether-ß-cyclodextrin as the sole excipient in certain formulations, with trace amounts of organic solvents allowed. Overall, the patent highlights the development of a lyophilized pharmaceutical preparation that offers improved solubility and stability in aqueous solutions, potentially enhancing the delivery and efficacy of the active pharmaceutical ingredient.

To know more about GlobalData’s detailed insights on Oncopeptides, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies